


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.80%
-0.04%
-1.71%
+1.50%
SNGX
Soligenix
$1.44
Strengths

Earnings are forecast to grow
SNGX Price Performance
$1.47 (-2.04%)
$1.16 (+24.14%)
$3.11 (-53.70%)
$3.22 (-55.28%)
SNGX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Investors losing confidence

Price under $5

Low volume

SNGX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
SNGX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
SNGX Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
What is SNGX current stock price?
What are SNGX stock strengths?
What is SNGX Risk Level?
What is SNGX market cap and volume?
What is SNGX current Stock IQ?
Should I buy SNGX stock right now?
Is SNGX a Strong Buy right now?
What does a 'Strong Buy' rating mean for SNGX?
What does a 'Strong Sell' rating mean for SNGX?
What factors influence SNGX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.80%
-0.04%
-1.71%
+1.50%
SNGX
Soligenix
Current Price
$1.44
Stock Insights
Strengths

Earnings are forecast to grow

SNGX Price Performance
$1.47 (-2.04%)
$1.16 (+24.14%)
$3.11 (-53.70%)
$3.22 (-55.28%)
SNGX Analysts Opinion
SNGX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
SNGX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
SNGX Street Sentiment is extremely bullish and have positive views on the near-term outlook
SNGX has Extreme risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Investors losing confidence

Price under $5

Low volume

Average key support and resistance price levels
SNGX Stock IQ
SNGX Latest Analysis
SNGX: Positive Results for Phase 2a Trial in Psoriasis. By Business UpdatePositive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis TrialOn December 17 2025 Soligenix Inc. (NASDAQ:SNGX) announced positive results from Cohort 3 of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. Cohort 3 consisted of four patients who were enrolled and treated with an improved topical gel formulation of synthetic hypericin. The gel formulation was des
Mon Dec 22, 2025
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel. ) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-.In this extension (Cohort 3) of the exploratory phase of the study an additional four patients were enrolled and treated with an improved topical gel formulation of synthetic hypericin.The gel formulation was specifically designed to improve ease of application to larger areas of the skin.SGX302 gel therapy wa
Wed Dec 17, 2025
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis. Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON N.J. Dec. 17 2025 /PRNewswire/ -- Soligenix Inc. (Nasdaq: SNGX) (Soligenix or the Company) a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
Wed Dec 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SNGX Stock trends
SNGX Stock performance
SNGX Stock analysis
SNGX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.